130 related articles for article (PubMed ID: 33723135)
1. The role of volumetric method in the assessment of chemotherapy response and predicting survival in malignant pleural mesothelioma.
Urfali FE; Metintas S; Gurgen A; Guntulu AK; Ozkan R; Metintas M
J Cancer Res Ther; 2021; 17(1):69-74. PubMed ID: 33723135
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
Vivoda Tomšič M; Bisdas S; Kovač V; Serša I; Šurlan Popovič K
Cancer Imaging; 2019 Feb; 19(1):10. PubMed ID: 30813957
[TBL] [Abstract][Full Text] [Related]
5. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K
Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245
[TBL] [Abstract][Full Text] [Related]
6. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
Armato SG; Nowak AK
J Thorac Oncol; 2018 Jul; 13(7):1012-1021. PubMed ID: 29753121
[TBL] [Abstract][Full Text] [Related]
7.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
8. Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria.
Kidd AC; Anderson O; Cowell GW; Weir AJ; Voisey JP; Evison M; Tsim S; Goatman KA; Blyth KG
Thorax; 2022 Dec; 77(12):1251-1259. PubMed ID: 35110367
[TBL] [Abstract][Full Text] [Related]
9. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Li F; Ahmad M; Qayyum F; Straus CM; MacMahon H; Kindler H; Armato SG
Eur Radiol; 2019 Jun; 29(6):2981-2988. PubMed ID: 30617480
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
Vivoda Tomšič M; Korošec P; Kovač V; Bisdas S; Šurlan Popovič K
BMC Cancer; 2022 Feb; 22(1):191. PubMed ID: 35184730
[TBL] [Abstract][Full Text] [Related]
12. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
[TBL] [Abstract][Full Text] [Related]
13. The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis.
Voigt SL; Raman V; Jawitz OK; Bishawi M; Yang CJ; Tong BC; D'Amico TA; Harpole DH
J Natl Cancer Inst; 2020 Nov; 112(11):1118-1127. PubMed ID: 32011691
[TBL] [Abstract][Full Text] [Related]
14. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
[TBL] [Abstract][Full Text] [Related]
16. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
Byrne MJ; Nowak AK
Ann Oncol; 2004 Feb; 15(2):257-60. PubMed ID: 14760119
[TBL] [Abstract][Full Text] [Related]
17. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
Labby ZE; Armato SG; Dignam JJ; Straus C; Kindler HL; Nowak AK
J Thorac Oncol; 2013 Apr; 8(4):478-86. PubMed ID: 23486268
[TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
[TBL] [Abstract][Full Text] [Related]
20. Optimization of response classification criteria for patients with malignant pleural mesothelioma.
Labby ZE; Armato SG; Kindler HL; Dignam JJ; Hasani A; Nowak AK
J Thorac Oncol; 2012 Nov; 7(11):1728-34. PubMed ID: 23059782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
